|Articles|September 17, 2020
Nitrosamine Testing: The Regulatory Aspects
Author(s)SGS
Detection of N-Nitrosodimethylamine (NDMA) impurities has led to regulatory warnings and product recalls. Pharmaceutical manufacturers must adopt a proactive approach to risk assessment and mitigation in relation to genotoxic contaminants.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Immortal Dragons Will Help Etheros Target Aging and Related Diseases
2
PharmTech Weekly News Roundup – Week of December 1, 2025
3
Drug Digest: Closing the Gap in Modern Process Control and Automation for QC/QA
4
Raman Spectroscopy—A Game-Changer in the Fight Against Counterfeit Drugs
5
